ATHA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATHA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2025-03-19), Athira Pharma's 14-Day RSI is 33.73.
The industry rank for Athira Pharma's 14-Day RSI or its related term are showing as below:
For the Biotechnology subindustry, Athira Pharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Athira Pharma's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Athira Pharma's 14-Day RSI falls into.
The formula for calculating RSI is:
RSI | = | 100 | – | [ 100 | / | ( 1 + Average Gain | / | Average Loss )] |
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Athira Pharma (NAS:ATHA) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Thank you for viewing the detailed overview of Athira Pharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark James Litton | officer: Chief Operating Officer | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Mark Worthington | officer: General Counsel | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Kevin Church | officer: Vice President of Discovery | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Rachel Lenington | officer: Chief Technology Officer | C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011 |
Andrew Gengos | officer: See Below | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Kelly A Romano | director | C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Grant Pickering | director | C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070 |
James A Johnson | director | C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102 |
Glenna Mileson | officer: Chief Financial Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Hans Moebius | officer: Chief Medical Officer | 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141 |
Michael A. Panzara | director | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Barbara Kosacz | director | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By Marketwired • 11-07-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 06-26-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 12-06-2024
By Marketwired • 05-02-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.